TWO CLINICAL PROOF-OF-CONCEPT TRIALS OF BLU-667 AND OSIMERTINIB IN COMBINATION WITH THE TREATMENT OF NSCLC RESULTED IN POSITIVE RESULTS

Today, Blueprint Medicines at the World Lung CancerConferenceorganized by the International Association for Lung Cancer Research (at theof the Study of The Study of Specific RET Receptor Inhibitors, BLU-667 and Osimertinib (Astrazenc's Tagrisso), the results of two clinical
lysing non-small cell lung cancer (NSCLC) trials(positive results) for patients with refractory non-small cell lung cancer (NSCLC) who carry eGFR gene mutationsTheabout THE BLU-667
BLU-667 is a daily oral strong RET-specific inhibitor developed by Blueprint Medicines, specifically targeting cancer-causing RET fusion and mutationsIn preclinical studies, BLU-667 showed a persistent sub-nanomolar level response to a variety of common RET fusion, mutation, and drug-resistant mutationsCompared to several approved MKIs, the BLU-667's selectivity to the RET is significantly increased, and the VEGFR-2 is more than 80 times higherby suppressing stage1 and stage 2 mutations, BLU-667 has the potential to overcome and prevent clinically resistant mutationsThis will enable BLUE-667 to achieve a continuous clinical positive response to multiple RET mutations and good safetyin addition to this, the drug is currently being evaluated in a worldwide Phase 1 clinical trial of NSCLC, MTC and other solid tumor patients with RET variantsBlueprint Medicines announced ARROW's positive results at the American Association for Cancer Research (AACR) 2018 annual meeting in Aprilthe trial included 19 NSCLC patients, 29 MTC patients and 5 other patients with solid tumorsThe 53 patients received an increased dose of BLU-667, of which 27 had previously been treated with MKIs and 18 had received immunotherapy results showed that 84% of patients with RET-mutated solid tumors with lesions can be detected (tumors in patients have shrunk and BLU-667 is resistant.) clinical data from the the combined therapy, published this time, showed that two patients who participated in the trial with a severe NSCLC with mutations in the EGFR gene received partial remission (PR) after eight weeks of combined therapy Both severe patients involved in the trial had received pre-treatment and had become incurable to standard treatment due to the RET fusion gene According to the evaluation of solid tumor efficacy standard (RECIST) version 1.1, the tumors of each patient were reduced by 78%, and the combination therapy was well resistant